Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China

Lung cancer causes significant morbidity and mortality in China and worldwide. In China, lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, accounting for approximately 80%–85% of all lung cancer cases. Immunoth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anwen Xiong, Jiali Wang, Caicun Zhou
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	non-small cell lung cancer (NSCLC) immunotherapy immune checkpoint inhibitors (ICI) pembrolizumab China Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/85401136b19c4d6bb7c8f3bf245ae86f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:85401136b19c4d6bb7c8f3bf245ae86f
record_format	dspace
spelling	oai:doaj.org-article:85401136b19c4d6bb7c8f3bf245ae86f2021-11-30T20:58:15ZImmunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China2234-943X10.3389/fonc.2021.757993https://doaj.org/article/85401136b19c4d6bb7c8f3bf245ae86f2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.757993/fullhttps://doaj.org/toc/2234-943XLung cancer causes significant morbidity and mortality in China and worldwide. In China, lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, accounting for approximately 80%–85% of all lung cancer cases. Immunotherapy with immune checkpoint inhibitors (ICIs) is revolutionizing the treatment of NSCLC. Immune checkpoint molecules, including PD-1/PD-L1 and CTLA-4, can suppress immune responses by delivering negative signals to T cells. By interfering with these immunosuppressive axes, ICIs unleash antitumor immune responses, ultimately eliminating cancer cells. ICIs have demonstrated promising antitumor efficacy in NSCLC, and mounting evidence supports the use of ICIs in treatment-naïve patients with advanced NSCLC. A comprehensive overview of current and emerging ICIs for the first-line treatment of NSCLC in China will facilitate a better understanding of NSCLC immunotherapy using ICIs and optimize the clinical use of ICIs in previously untreated Chinese patients with NSCLC. Herein, we review the efficacy and safety of currently approved and investigational ICIs as the first-line treatment of NSCLC in China. We also discuss the challenges limiting more widespread use of ICIs and future directions in the first-line treatment of NSCLC using ICIs.Anwen XiongJiali WangCaicun ZhouFrontiers Media S.A.articlenon-small cell lung cancer (NSCLC)immunotherapyimmune checkpoint inhibitors (ICI)pembrolizumabChinaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer (NSCLC) immunotherapy immune checkpoint inhibitors (ICI) pembrolizumab China Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer (NSCLC) immunotherapy immune checkpoint inhibitors (ICI) pembrolizumab China Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Anwen Xiong Jiali Wang Caicun Zhou Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
description	Lung cancer causes significant morbidity and mortality in China and worldwide. In China, lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, accounting for approximately 80%–85% of all lung cancer cases. Immunotherapy with immune checkpoint inhibitors (ICIs) is revolutionizing the treatment of NSCLC. Immune checkpoint molecules, including PD-1/PD-L1 and CTLA-4, can suppress immune responses by delivering negative signals to T cells. By interfering with these immunosuppressive axes, ICIs unleash antitumor immune responses, ultimately eliminating cancer cells. ICIs have demonstrated promising antitumor efficacy in NSCLC, and mounting evidence supports the use of ICIs in treatment-naïve patients with advanced NSCLC. A comprehensive overview of current and emerging ICIs for the first-line treatment of NSCLC in China will facilitate a better understanding of NSCLC immunotherapy using ICIs and optimize the clinical use of ICIs in previously untreated Chinese patients with NSCLC. Herein, we review the efficacy and safety of currently approved and investigational ICIs as the first-line treatment of NSCLC in China. We also discuss the challenges limiting more widespread use of ICIs and future directions in the first-line treatment of NSCLC using ICIs.
format	article
author	Anwen Xiong Jiali Wang Caicun Zhou
author_facet	Anwen Xiong Jiali Wang Caicun Zhou
author_sort	Anwen Xiong
title	Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
title_short	Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
title_full	Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
title_fullStr	Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
title_full_unstemmed	Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
title_sort	immunotherapy in the first-line treatment of nsclc: current status and future directions in china
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/85401136b19c4d6bb7c8f3bf245ae86f
work_keys_str_mv	AT anwenxiong immunotherapyinthefirstlinetreatmentofnsclccurrentstatusandfuturedirectionsinchina AT jialiwang immunotherapyinthefirstlinetreatmentofnsclccurrentstatusandfuturedirectionsinchina AT caicunzhou immunotherapyinthefirstlinetreatmentofnsclccurrentstatusandfuturedirectionsinchina
_version_	1718406275362979840

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China

Ejemplares similares